TOP
2021 - 03 - 01
Fapon Biotech new reagent raw materials and test components for the latex-enhanced immunoturbidimetric platform is now added to the COVID-19/SARS-CoV-2 Neutralizing Antibody Test Solution. Products for ELISA, CLIA and CMIA, had introduced earlier in supporting customers’ NAb test development and vaccine effectiveness evaluation. With the company mission, ‘Enable Earlier Disease Identification, More Convenient, Accurate and Affordable Diagnosis’, continues to illuminate each action made during the pandemic, Fapon Biotech seeks ongoing innovations to support pandemic diagnosis and control. Curre...
2021 - 02 - 19
Fapon Biotech makes persist efforts to deal with the global pandemic new challenge, introduces COVID-19 Variant E484K POCT Solution for the effective differentiation of E484K and non-E484K infection. Previously, the company took a significant innovative step for being the first in the world in launching POCT Solution for variant B.1.1.7 (VUI 202012/01) and wild-type virus differentiation (https://bit.ly/3qDsmky). These solutions using POCT mechanism to offer additional values to the variant diagnosis using genome sequencing and PCR technologies, being an excellent mean to fight against the glo...
2021 - 01 - 20
Fapon Biotech is pleased to confirm the effective detection of its COVID-19 antibodies to the mainstream variants, B.1.1.7(also known as SARS-CoV-2 VUI 202012/01) and B.1.351 (known as 501Y.V2) after implemented evaluation using recombinant NP antigens.The evaluations showed the same reaction to wild-type strains, confirming the effective detection to COVID-19 variants and wild-type strains with no omission in test results.  Fapon Biotech has a strong position in the fight of COVID-19. Its antibody pairs have the best-in-class specificity, which had been widely used by global reagent manu...
2021 - 01 - 17
Fapon Biotech, a mainstream COVID-19 raw materials supplier to the global top-profile reagent manufacturers, introduced pioneering COVID-19 antibodies for antigen lateral flow testing to detect and differentiate COVID-19 and the most notable variant B.1.1.7 (also known as SARS-CoV-2 VUI 202012/01) in human samples.Variant strain surveillance is vital for COVID-19 control. Variants such as B.1.1.7 that causes 40-70% higher transmissibility and false-negative results on some PCR tests had drawn concerns and investigation from scientists and healthcare authorities like WHO, FDA and others. Accord...
15页次1/4首页 1234 尾页